文献速递乳腺癌

MRI引导优化II-III期HER2阳性乳腺癌新辅助化疗疗程(TRAIN-3):多中心单臂2期研究

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
PubMed 文献 · Lancet Oncol · 2024-04-05

TRAIN-3是一项在荷兰43家医院开展的单臂2期研究,纳入II-III期HER2阳性乳腺癌患者,根据乳腺MRI每3周期评估的影像学反应决定手术时机或最多9周期化疗。激素受体阴性患者1-9周期影像学完全缓解者中病理完全缓解147/169(87%);激素受体阳性患者为73/138(53%)。研究认为MRI完全缓解有助于识别激素受体阴性肿瘤的早期完全缓解者,激素受体阳性患者需要更好的监测工具。

要点

  • 激素受体阴性患者1-3周期影像学完全缓解84/233(36%),1-9周期为169/233(73%)。
  • 影像学完全缓解者中病理完全缓解:激素受体阴性147/169(87%),激素受体阳性73/138(53%)。
  • 3-4级不良事件最常见为中性粒细胞减少175/467(37%)、贫血75/467(16%)、腹泻57/467(12%),未报告治疗相关死亡。

核心结论

  • 本研究中,II-III期激素受体阴性HER2阳性乳腺癌患者中三分之一在仅3周期新辅助全身治疗后达到病理完全缓解。
  • 乳腺MRI完全缓解可能有助于识别激素受体阴性肿瘤的早期完全缓解者。
  • 基于影像的策略可能限制这些患者的化疗疗程、减少副作用并维持生活质量,但需待3年无事件生存主要终点分析确认。
  • 激素受体阳性HER2阳性乳腺癌患者需要更好的监测工具。

研究设计与样本

  • TRAIN-3为单臂2期研究,在荷兰43家医院开展。
  • 纳入年龄18岁及以上、WHO体能状态0或1的II-III期HER2阳性乳腺癌患者。
  • 患者接受紫杉醇(80 mg/m2体表面积,每21天周期第1天和第8天静脉给药)、曲妥珠单抗(第1周期第1天负荷剂量8 mg/kg体重,后续周期第1天6 mg/kg)、卡铂(浓度-时间曲线下面积6 mg/mL每min,每3周周期第1天)和帕妥珠单抗(第1周期第1天负荷剂量840 mg,后续周期第1天420 mg),均静脉给药。
  • 每3周期通过乳腺MRI和淋巴结活检监测反应;达到影像学完全缓解或最多9周期治疗后行手术。
  • 主要终点为3年无事件生存,随访正在进行;本文报告所有手术患者的影像学和病理学缓解率(次要终点)及所有至少接受1周期治疗患者的毒性数据,分析按激素受体阳性和阴性分别进行。

主要发现

  • 233例激素受体阴性肿瘤患者中,影像学完全缓解在1-3周期后为84例(36%;95% CI 30-43),1-6周期后为140例(60%;53-66),1-9周期后为169例(73%;66-78)。
  • 232例激素受体阳性肿瘤患者中,影像学完全缓解在1-3周期后为68例(29%;24-36),1-6周期后为118例(51%;44-57),1-9周期后为138例(59%;53-66)。
  • 1-9周期后影像学完全缓解的患者中,病理完全缓解在激素受体阴性肿瘤为147/169例(87%;95% CI 81-92),在激素受体阳性肿瘤为73/138例(53%;44-61)。
  • 最常见的3-4级不良事件为中性粒细胞减少175/467例(37%)、贫血75/467例(16%)、腹泻57/467例(12%)。
  • 未报告治疗相关死亡。

临床怎么用

  • 作者认为,乳腺MRI完全缓解可能有助于识别激素受体阴性肿瘤的早期完全缓解者。
  • 作者认为,基于影像的策略可能限制这些患者的化疗疗程、减少副作用并维持生活质量,但需待3年无事件生存主要终点分析确认。
  • 作者认为,激素受体阳性HER2阳性乳腺癌患者需要更好的监测工具。

局限性

  • 主要终点3年无事件生存的随访仍在进行中,本文仅报告次要终点的影像学和病理学缓解率及毒性数据。
  • 作者指出基于影像的策略需待3年无事件生存主要终点分析确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with stage II-III HER2-positive breast cancer have good outcomes with the combination of neoadjuvant chemotherapy and HER2-targeted agents. Although increasing the number of chemotherapy cycles improves pathological complete response rates, early complete responses are common. We investigated whether the duration of chemotherapy could be tailored on the basis of radiological response. METHODS: TRAIN-3 is a single-arm, phase 2 study in 43 hospitals in the Netherlands. Patients with stage II-III HER2-positive breast cancer aged 18 years or older and a WHO performance status of 0 or 1 were enrolled. Patients received neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2 of body surface area on day 1 and 8 of each 21 day cycle), trastuzumab (loading dose on day 1 of cycle 1 of 8 mg/kg bodyweight, and then 6 mg/kg on day 1 on all subsequent cycles), and carboplatin (area under the concentration time curve 6 mg/mL per min on day 1 of each 3 week cycle) and pertuzumab (loading dose on day 1 of cycle 1 of 840 mg, and then 420 mg on day 1 of each subsequent cycle), all given intravenously. The response was monitored by breast MRI every three cycles and lymph node biopsy. Patients underwent surgery when a complete radiological response was observed or after a maximum of nine cycles of treatment. The primary endpoint was event-free survival at 3 years; however, follow-up for the primary endpoint is ongoing. Here, we present the radiological and pathological response rates (secondary endpoints) of all patients who underwent surgery and the toxicity data for all patients who received at least one cycle of treatment. Analyses were done in hormone receptor-positive and hormone receptor-negative patients separately. This trial is registered with ClinicalTrials.gov, number NCT03820063, recruitment is closed, and the follow-up for the primary endpoint is ongoing. FINDINGS: Between April 1, 2019, and May 12, 2021, 235 patients with hormone receptor-negative cancer and 232 with hormone receptor-positive cancer were enrolled. Median follow-up was 26·4 months (IQR 22·9-32·9) for patients who were hormone receptor-negative and 31·6 months (25·6-35·7) for patients who were hormone receptor-positive. Overall, the median age was 51 years (IQR 43-59). In 233 patients with hormone receptor-negative tumours, radiological complete response was seen in 84 (36%; 95% CI 30-43) patients after one to three cycles, 140 (60%; 53-66) patients after one to six cycles, and 169 (73%; 66-78) patients after one to nine cycles. In 232 patients with hormone receptor-positive tumours, radiological complete response was seen in 68 (29%; 24-36) patients after one to three cycles, 118 (51%; 44-57) patients after one to six cycles, and 138 (59%; 53-66) patients after one to nine cycles. Among patients with a radiological complete response after one to nine cycles, a pathological complete response was seen in 147 (87%; 95% CI 81-92) of 169 patients with hormone receptor-negative tumours and was seen in 73 (53%; 44-61) of 138 patients with hormone receptor-positive tumours. The most common grade 3-4 adverse events were neutropenia (175 [37%] of 467), anaemia (75 [16%]), and diarrhoea (57 [12%]). No treatment-related deaths were reported. INTERPRETATION: In our study, a third of patients with stage II-III hormone receptor-negative and HER2-positive breast cancer had a complete pathological response after only three cycles of neoadjuvant systemic therapy. A complete response on breast MRI could help identify early complete responders in patients who had hormone receptor negative tumours. An imaging-based strategy might limit the duration of chemotherapy in these patients, reduce side-effects, and maintain quality of life if confirmed by the analysis of the 3-year event-free survival primary endpoint. Better monitoring tools are needed for patients with hormone receptor-positive and HER2-positive breast cancer. FUNDING: Roche Netherlands.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. van der Voort A, Louis FM, van Ramshorst MS, et al. MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024. PMID: 38588682. doi:10.1016/S1470-2045(24)00104-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。